The STIM-ADHF Study

Cardionomic Inc.13 enrolled

Overview

The STIM-ADHF Study is a multi-center, observational study to assess the performance and safety of the CPNS System in patients with ADHF.

The CPNS System is a neuromodulation system used to treat ADHF, a sudden or slow deterioration of chronic heart failure. The CPNS system is intended to provide acute (≤ 5 days) endovascular stimulation of the cardiac autonomic nerves in the right pulmonary artery (PA) in hospitalized ADHF patients. The system consists of an acute temporary neuromodulation stimulation catheter placed in the right pulmonary artery via venous access and a custom stimulator, denoiser, and associated cables. The CN2 Catheter is delivered to the right PA and provides an inotropic and/or lusitropic therapeutic effect by electrical stimulation to the terminal sympathetic nerve branches within the cardio-pulmonary plexus. The study will be conducted at up to 20 study sites worldwide. Up to 50 subjects who meet the eligibility criteria, will be enrolled, treated in-hospital with the Cardionomic CPNS System, monitored closely throughout the hospitalization and followed through 30 days post hospital discharge to evaluate the effect of the CPNS treatment.

Study Type

INTERVENTIONAL

Allocation

Purpose

TREATMENT

Masking

NONE

Enrollment

Conditions

Acute Decompensated Heart Failure

Interventions

CPNS TherapyDEVICE

Endovascular stimulation of the cardiac autonomic nerves in addition to standard of care

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Admitted to the hospital or planned to be admitted with a principal diagnosis of acute decompensated heart failure * BMI adjusted BNP ≥ 500 pg/mL or NT-proBNP ≥ 2000 pg/mL * LVEF ≤ 50% * At least one sign/symptom of fluid overload * At least one of the following: * Inadequate diuretic response * At least one sign or symptom of low perfusion Exclusion Criteria: * Received an inotrope during current hospitalization * Requires mechanical support * Cardiogenic shock or impending cardiogenic shock * Multi-organ failure * Systolic blood pressure \< 80mmHg or \> 140mmHg * Symptomatic hypotension * eGFR \< 25 mL/min/1.732 * Severe hepatic disease

Locations (6)

Semmelweis University, Heart and Vascular Center

Budapest, Hungary

Hearth Faculty of Medicine, University of Pécs

Pécs, Hungary

Szegedi Tudományegyetem ÁOK

Szeged, Hungary

American Heart of Poland

Bielsko-Biala, Poland

Outcomes

Primary Outcomes

Occurrence of related adverse events

The following measures will be characterized in all enrolled subjects: occurrence of all procedure, device and therapy related adverse events, serious adverse events and deaths

Time frame: Enrolment to 30 Days post hospital discharge

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.